STOCK TITAN
  1. Home
  2. News
  3. CLLS

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated news page for Cellectis (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectis's position in the market.

News
Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) to hold a general meeting on December 22, 2023, at 2:30 p.m. CET at the Biopark auditorium in Paris, France. The notice of meeting, agenda, resolutions, and terms of participation are available on the Cellectis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) has signed a binding Subsequent Investment Agreement with AstraZeneca regarding the additional equity investment of $140M previously announced. AstraZeneca will subscribe to 10,000,000 'class A' convertible preferred shares and 18,000,000 'class B' convertible preferred shares at $5.00 per share. The approval of an extraordinary shareholders’ meeting of Cellectis and clearance from the French Ministry of Economy are required before the closing of the investment, which is expected to result in AstraZeneca owning approximately 44% of the share capital and 30% of the voting rights of Cellectis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
News
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has signed strategic collaboration and investment agreements with AstraZeneca. The collaboration will leverage Cellectis' gene editing technologies to develop next-generation therapeutics in areas of high unmet need. Cellectis' clinical-stage assets will remain under its ownership. The company also provided updates on its clinical trials and preclinical programs, including the BALLI-01 trial evaluating UCART22 and the NATHALI-01 trial evaluating UCART20x22. Cellectis has a cash position of $721 million as of September 30, 2023, providing a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.41%
Tags
earnings
News
Monthly information on share capital and company voting rights
Rhea-AI Summary
Cellectis, a company listed on Euronext Growth, has a total of 55,583,768 shares in its capital and 61,519,396 voting rights as of October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
Rhea-AI Summary
Cellectis announced that preliminary results of the Phase I NATHALI-01 clinical trial and updated results of the Phase I BALLI-01 clinical trial will be presented at the ASH 2023. The data shows positive responses in patients with relapsed or refractory non-Hodgkin lymphoma and CD22+ B-cell acute lymphoblastic leukemia. No dose limiting toxicities were observed, and the studies continue to enroll patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences
-
News
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, will report financial results for Q3 2023 on November 6, 2023. An investor conference call and webcast will be held on November 7, 2023, providing an update on business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.02%
Tags
conferences earnings
News
Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
Rhea-AI Summary
Cellectis has entered into a collaboration agreement, investment agreement, and memorandum of understanding with AstraZeneca. AstraZeneca will leverage Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell and gene therapy candidate products. Cellectis will receive up to $245M in cash, including an upfront payment of $25M and potential milestone payments and royalties. AstraZeneca will make an initial equity investment of $80M and a potential additional investment of $140M. Cellectis' clinical-stage assets will remain under its ownership and control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
172.16%
Tags
none
-
News
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on MUC1-CAR T-cells at the Society for Immunotherapy of Cancer's 38th Annual Meeting. The data demonstrates the enhanced activity and reduced off-tumor toxicity of the cells when combined with ΔPD1-IL12 and TGFBR2-KO attributes in preclinical models of triple negative breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
172.16%
Tags
clinical trial
-
News
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
Rhea-AI Summary
Cellectis to showcase pre-clinical data on gene therapy program at ESGCT congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences clinical trial
News
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
Rhea-AI Summary
Cellectis announces new research paper demonstrating gene correction efficacy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Stock CLLS logo
Cellectis

Nasdaq:CLLS

CLLS Rankings

#3859 Ranked by Market Cap
#4900 Ranked by Stock Gains
N/A Ranked by Dividends

CLLS Stock Data

203.24M
33.22M
12.13%
18.83%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
France
Paris

About CLLS

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.